Company news

AstraZeneca PLC news in 2025

AstraZeneca PLC's news releases, calls and decks from 2025, newest first.

View company

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

December 22, 2025

Director/PDMR Shareholding

December 22, 2025

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer

December 22, 2025

Enhertu granted BTD for post-neoadjuvant early BC

December 22, 2025

Update on LATIFY Phase III trial of ceralasertib

December 22, 2025

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

December 21, 2025

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

December 18, 2025

Subcutaneous Saphnelo approved in EU

December 16, 2025

Enhertu approved in US for 1L HER2+ metastatic BC

December 16, 2025

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

December 15, 2025

ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

December 15, 2025

DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer

December 9, 2025

Correction: Pillar Biosciences, Inc.

December 7, 2025

China's Licensing Trends Shaping Global Drug Development Analysis Report 2025: Parent Companies Benefitted from Upfront Payments for R&D, Gaining Equity in Novel Chinese Therapeutics

December 5, 2025

Salesforce’s Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

December 4, 2025

Holding(s) in Company

December 4, 2025

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

December 4, 2025

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

December 2, 2025

Block listing Interim Review

December 1, 2025

IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

November 26, 2025

Imfinzi approved in US for early gastric cancer

November 26, 2025

AstraZeneca manufacturing investment in Maryland

November 24, 2025

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

November 23, 2025

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

November 21, 2025

Koselugo (selumetinib) approved in the US

November 20, 2025

ENGIE to Supply Planet-Friendly Power to AstraZeneca Texas Manufacturing Site

November 12, 2025

FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update

November 10, 2025

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

November 9, 2025

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease

November 7, 2025

AstraZeneca's 9M and Q3 2025 Financial Results

November 6, 2025

9M and Q3 2025 results

November 6, 2025

Alliance for Building Better Medicine and the Virginia Innovation Partnership Celebrate $120 Million Investment from AstraZeneca, Eli Lilly, and Merck to Advance Virginia's Advanced Pharmaceutical Manufacturing Workforce

November 5, 2025

Breakthrough Properties Completes One Helix, A Cutting-edge Research Facility Fully Leased to AstraZeneca

November 4, 2025

Result of General Meeting

November 3, 2025

The Craneware Group Hosts 340B Rebate Forum, Confirms No New Vendor Needed for Pilot

October 31, 2025

DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer

October 30, 2025

Director Declaration

October 28, 2025

Koselugo (selumetinib) approved in the EU

October 28, 2025

United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall

October 23, 2025

Tezspire Approved in EU for CRSwNP

October 22, 2025

US FDA Approves Tezspire in CRSwNP

October 20, 2025

Positive CHMP opinion for subcutaneous Saphnelo

October 20, 2025

DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option

October 19, 2025

DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02

October 19, 2025

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial

October 18, 2025

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial

October 18, 2025

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

October 17, 2025

DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial

October 17, 2025

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial

October 17, 2025

IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

October 17, 2025

Older news releases →

Calls in 2025

Decks in 2025